NECVAX-NEO1

BIOLOGICAL2 trials

Sponsors

NEC OncoImmunity AS, NEC Bio B.V

Conditions

Solid TumorSolid Tumors, Adult

Phase 1

NECVAX-NEO1 in Addition to Checkpoint Inhibitor in Patients With Solid Tumors

Active, not recruitingNCT05354323

NEC OncoImmunity ASSolid Tumors, Adult

Start: 2022-05-05End: 2025-12-31Updated: 2025-06-26

Personalised Neoantigen-targeting Cancer Vaccine NECVAX-NEO1 in Anti-PD-1/PD-L1 Therapy in Patients With Solid Tumors

Active, not recruitingNCT06631079

NEC Bio B.VSolid Tumor

Start: 2024-10-07End: 2028-12-31Target: 20Updated: 2026-01-08